NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT07033598 2026-03-05
PROSPERA
Theradex
Phase 2 Recruiting
NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT03944915 2025-05-11
DEPEND
University of Chicago
Phase 2 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed